Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596933 | 0.90 | RORC (0.44) | ACHECHRM2CHRM3LMNA | |
| SCHEMBL6043641 | 0.90 | ACHE (0.42) | ACHE | |
| SCHEMBL7596934 | 0.90 | RORC (0.44) | ACHECHRM2CHRM3LMNA | |
| SCHEMBL6043648 | 0.90 | ACHE (0.42) | ACHE | |
| SCHEMBL7138824 | 0.85 | ALDH1A1 (0.47) | ACHECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14635919 | 0.80 | MEN1 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3624555 | 0.78 | PRMT1 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL10431124 | 0.78 | CYP2D6 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6652157 | 0.77 | CYP2D6 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6332780 | 0.76 | DRD2 (0.38) | ACHEFUCA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | ACHE 3594/4885CHRM2 629/4885CHRM4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.